|
See related Xarelto film-coated tab information |
|
|
|
Manufacturer |
Bayer |
|
Distributor |
Hong Kong: Zuellig/Macau: Firma Chun Cheong |
|
Contents |
Rivaroxaban |
|
Indications |
Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.
Click to view Xarelto detailed prescribing infomation |
|
Dosage |
10 mg once daily. Initial dose should be taken 6-10 hr after surgery, provided that haemostasis has been established. Duration of treatment: Major hip surgery 5 wk. Major knee surgery 2 wk.
Click to view Xarelto detailed prescribing infomation |
|
Overdosage |
View Xarelto overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Childn & adolescent <18 yr. Pregnancy & lactation.
Click to view Xarelto detailed prescribing infomation |
|
Special Precautions |
Haemorrhagic risk; congenital or acquired bleeding disorders; uncontrolled severe arterial HTN; active & recent GI ulcerations; vascular retinopathy; recent intracranial or intracerebral haemorrhage; intraspinal or intracerebral vascular abnormalities; recent brain, spinal or ophthalmological surgery; hip fracture surgery; spinal/epidural anaesth or puncture. Renal & hepatic impairment.
Click to view Xarelto detailed prescribing infomation |
|
Adverse Drug Reactions |
Increased GGT, increase in transaminases (ALT & AST); anaemia; nausea; postprocedural haemorrhage.
View ADR Monitoring Form |
|
Drug Interactions |
Azole antimycotics eg ketoconazole, itraconazole, voriconazole, posaconazole, fluconazole; HIV-protease inhibitors. CYP3A4 inducers eg phenytoin, carbamazepine, phenobarb or St. John's wort.
View more drug interactions with Xarelto |
|
Storage |
View Xarelto storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Xarelto description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Xarelto mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
